Clinical importance of the EMSY gene expression and polymorphisms in ovarian cancer.
Ontology highlight
ABSTRACT: EMSY, a BRCA2-associated protein, is amplified and overexpressed in various sporadic cancers. This is the first study assessing the clinical impact of its expression and polymorphisms on ovarian cancer (OvCa) outcome in the context of the chemotherapy regimen used. In 134 frozen OvCa samples, we assessed EMSY mRNA expression with Reverse Transcription-quantitative PCR, and also investigated the EMSY gene sequence using SSCP and/or PCR-sequencing. Clinical relevance of changes in EMSY mRNA expression and DNA sequence was evaluated in two subgroups treated with either taxane/platinum (TP, n=102) or platinum/cyclophosphamide (PC, n=32). High EMSY expression negatively affected overall survival (OS), disease-free survival (DFS) and sensitivity to treatment (PS) in t
SUBMITTER: Dansonka-Mieszkowska A
PROVIDER: S-EPMC5915152 | biostudies-literature | 2018 Apr
REPOSITORIES: biostudies-literature
ACCESS DATA